Ubiquigent Limited (“Ubiquigent”), a drug discovery and development company harnessing novel deubiquitinase (DUB) modulators as new therapeutics for areas of high unmet medical need, today announced a strategic partnership with Alleo Labs Corp. (“Alleo”), a pioneer in using artificial intelligence (AI) to develop new therapeutics for neurological diseases.
Alleo and Ubiquigent enter AI-driven strategic partnership to accelerate DUB-focused drug discovery
- Thread starter Educator
- Start date